Neoprobe Corp.
425 Metro Place North
Suite 300
Dublin,
OH 43017
United States - Map
Phone: 614-793-7500
Fax: 614-793-7520
Web Site: http://www.neoprobe.com
| Neoprobe Corporation, a biomedical company, develops and commercializes surgical and diagnostic products that enhance patient care by meeting the intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. The company primarily offers a line of gamma radiation detection equipment used in the application of sentinel lymph node biopsy (SLNB), and a line of blood flow monitoring devices for various diagnostic and surgical applications. Its products include neoprobe GDS gamma detection system; and Quantix/OR, which is designed to permit cardiovascular surgeons to obtain intraoperative volume blood flow readings in various targeted blood vessels within seconds. The company also holds developmental and/or intellectual property rights related to two drugs can be used in connection with gamma detection devices in cancer surgeries. Its drugs under development include Lymphoseek, which determines the spread of solid tumor cancers into the lymphatic system; and RIGScan CR that enables surgeons to locate cancerous or disease involved tissue during colorectal cancer surgeries. The company has a biopharmaceutical development and manufacturing agreement with Laureate Pharma Inc. for the production of murine monoclonal antibody CC49, known as RIGScan CR, a tumor-specific targeting agent intended for use in treatment of colorectal cancer. Neoprobe Corporation was founded in 1983 and is based in Dublin, Ohio. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. David C. Bupp , 60
Chief Exec. Officer, Pres |
N/A
| N/A | Mr. Brent L. Larson , 47
Chief Financial Officer, Principal Accounting Officer, VP of Fin., Sec. and Treasurer |
N/A
| N/A | Mr. Anthony K. Blair , 49
VP of Manufacturing Operations |
N/A
| N/A | Mr. Douglas L. Rash , 66
VP of Marketing |
N/A
| N/A | Mr. Rodger A. Brown , 59
VP of Regulatory Affairs and Quality Assurance |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.50% Nasdaq 
0.05 (4.10%) 
Profile
